2007
Energy balance, insulin resistance biomarkers, and breast cancer risk
Fair A, Dai Q, Shu X, Matthews C, Yu H, Jin F, Gao Y, Zheng W. Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer Epidemiology 2007, 31: 214-219. PMID: 17646056, PMCID: PMC1994998, DOI: 10.1016/j.cdp.2007.04.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAsian PeopleBiomarkersBody Mass IndexBreast NeoplasmsCase-Control StudiesChinaC-PeptideEnergy IntakeEnergy MetabolismExerciseFemaleHumansInsulin ResistanceInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IIMiddle AgedMotor ActivityRisk AssessmentRisk FactorsWaist-Hip RatioConceptsInsulin-like growth factorBreast cancer riskExercise/sports activitiesShanghai Breast Cancer StudyBody mass indexInsulin resistance biomarkersC-peptideCancer riskIGFBP-3Breast cancerLevels of IGFEnergy intakeInsulin growth factor binding protein 3Growth factor binding protein 3Chinese womenResistance biomarkersInsulin-like growth factor-1C-peptide levelsBreast cancer preventionPhysical activity statusSports activitiesTotal energy intakeBody fat distributionCase-control studyBreast cancer cases
2004
IGF‐I and breast cancer: A meta‐analysis
Shi R, Yu H, McLarty J, Glass J. IGF‐I and breast cancer: A meta‐analysis. International Journal Of Cancer 2004, 111: 418-423. PMID: 15221971, DOI: 10.1002/ijc.20233.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceIGFBP-3 levelsLevels of IGFIGF-binding proteinsBreast cancer riskStandardized mean differencePremenopausal womenBreast cancerIGFBP-3Cancer riskBreast cancer patientsEffects of IGFPostmenopausal womenPostmenopausal groupPremenopausal groupHigher IGFCancer patientsClinical studiesEpidemiologic studiesParacrine mechanismsIGFOverall associationMean differenceCancerWomen
2001
Insulin-like growth factor-I and prostate cancer: a meta-analysis
Shi R, Berkel H, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. British Journal Of Cancer 2001, 85: 991-996. PMID: 11592771, PMCID: PMC2375097, DOI: 10.1054/bjoc.2001.1961.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceLevels of IGFProstate cancer patientsStandardized mean differenceIGFBP-3Prostate cancerHigher IGFCancer patientsInsulin-like growth factorIGF-binding proteinsEffects of IGFCase-control studyLow IGFMEDLINE searchIGFMean differenceGrowth factorCancerPatientsStandard protocolRiskLevels
2000
Joint Effect of Insulin-Like Growth Factors and Mutagen Sensitivity in Lung Cancer Risk
Wu X, Yu H, Amos C, Hong W, Spitz M. Joint Effect of Insulin-Like Growth Factors and Mutagen Sensitivity in Lung Cancer Risk. Journal Of The National Cancer Institute 2000, 92: 737-743. PMID: 10793110, DOI: 10.1093/jnci/92.9.737.Peer-Reviewed Original ResearchMeSH Keywords7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxideBleomycinCase-Control StudiesChromosome AberrationsData Interpretation, StatisticalFemaleHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IILung NeoplasmsLymphocytesMaleMutagenicity TestsMutagensRisk FactorsSomatomedinsConceptsIGF-binding protein-3Lung cancer riskLung cancerCancer riskHigher IGFOdds ratioBPDE sensitivityInsulin-like growth factorMutagen sensitivityLevels of IGFPeripheral blood lymphocyte culturesLung cancer patientsSpecific histologic typesBleomycin sensitivityBlood lymphocyte culturesProliferation potentialHistologic typeTumor stageCancer patientsControl subjectsIGF-IIRisk factorsGenetic instabilityHumoral factorsLymphocyte cultures
1999
Insulin‐like growth factors (IGF‐I, free IGF‐I, and IGF‐II) and insulin‐like growth factor binding proteins (IGFBP‐2, IGFBP‐3, IGFBP‐6, and ALS) in blood circulation
Yu H, Mistry J, Nicar M, Khosravi M, Diamandis A, van Doorn J, Juul A. Insulin‐like growth factors (IGF‐I, free IGF‐I, and IGF‐II) and insulin‐like growth factor binding proteins (IGFBP‐2, IGFBP‐3, IGFBP‐6, and ALS) in blood circulation. Journal Of Clinical Laboratory Analysis 1999, 13: 166-172. PMID: 10414596, PMCID: PMC6808158, DOI: 10.1002/(sici)1098-2825(1999)13:4<166::aid-jcla5>3.0.co;2-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood CirculationBlood ProteinsCarrier ProteinsFemaleGlycoproteinsHumansImmunoassayInsulin-Like Growth Factor Binding Protein 2Insulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding Protein 6Insulin-Like Growth Factor IInsulin-Like Growth Factor IIMaleMiddle AgedProtein BindingReceptors, SomatomedinReference ValuesSomatomedinsConceptsInsulin-like growth factorTotal insulin-like growth factorIGF-II levelsIGFBP-3IGFBP-6Growth factorLevels of IGFFree insulin-like growth factorIGFBP-2 levelsIGFBP-2Plasma levelsEpidemiological studiesReference rangeNormal populationPubertyBlood circulationAgeSerumBirthCell growthALSMalesFemalesSimilar patternGenderPlasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis
Yu H, Spitz M, Mistry J, Gu J, Hong W, Wu X. Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis. Journal Of The National Cancer Institute 1999, 91: 151-156. PMID: 9923856, DOI: 10.1093/jnci/91.2.151.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorLung cancer riskHigher plasma levelsPlasma levelsIGFBP-3Lung cancerControl subjectsIGF-IICancer riskOdds ratioLevels of IGFIGFBP-3 plasma levelsGrowth factorIGFBP-3 levelsPlasma IGFBP-3Primary lung cancerIGF-binding proteinsCase-control studyLung cancer developmentCase-control analysisEnzyme-linked immunosorbentPossible causal roleIGF variablesCase patientsConsecutive patients